Repository logo
 
Publication

Immunotherapy in patients with advanced non-small cell lung cancer lacking driver mutations and future perspectives

2021-12-28Journal article Open Access
Simple item page
dc.contributor.authorDe Mello, Ramon Andrade Bezerra
dc.contributor.authorVoscaboinik, Rafael
dc.contributor.authorLuciano, João Vittor Pires
dc.contributor.authorCremonese, Rafaela Vilela
dc.contributor.authorAmaral, Giovanna Araujo
dc.contributor.authorCastelo-Branco, Pedro
dc.contributor.authorAntoniou, Georgios
dc.date.accessioned2022-01-13T15:14:53Z
dc.date.available2022-01-13T15:14:53Z
dc.date.issued2021-12-28
dc.date.updated2022-01-10T14:38:00Z
dc.description.abstractFrom a complete literature review, we were able to present in this paper what is most current in the treatment with immunotherapy for advanced non-small cell lung cancer (NSCLC). Especially the use of immunotherapy, particularly inhibitors of PD-1 (programmed cell death protein 1), PDL-1 (programmed cell death protein ligand 1), and CTLA-4 (cytotoxic T-lymphocyte antigen 4). Since 2015, these drugs have transformed the treatment of advanced NSCLC lacking driver mutations, evolving from second-line therapy to first-line, with excellent results. The arrival of new checkpoint inhibitors such as cemiplimab and the use of checkpoint inhibitors earlier in the therapy of advanced and metastatic cancers has been making the future prospects for treating NSCLC lacking driver mutations more favorable and optimistic. In addition, for those patients who have low PDL-1 positivity tumors, the combination of cytotoxic chemotherapy, VEGF inhibitor, and immunotherapy have shown an important improvement in global survival and progression free survival regardless the PDL-1 status. We also explored the effectiveness of adding radiotherapy to immunotherapy and the most current results about this combination. One concern that cannot be overlooked is the safety profile of immune checkpoint inhibitors (ICI) and the most common toxicities are described throughout this paper as well as tumor resistance to ICI.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifierdoi: 10.3390/cancers14010122
dc.identifier.citationCancers 14 (1): 122 (2022)pt_PT
dc.identifier.doi10.3390/cancers14010122pt_PT
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/10400.1/17480
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectImmunotherapypt_PT
dc.subjectAdvanced lung cancerpt_PT
dc.subjectDurvalumabpt_PT
dc.subjectPembrolizumabpt_PT
dc.subjectAtezolizumabpt_PT
dc.subjectIpilimumabpt_PT
dc.subjectNivolumabpt_PT
dc.subjectCemiplimabpt_PT
dc.subjectPD1pt_PT
dc.subjectPDL1pt_PT
dc.subjectAnti PD1pt_PT
dc.subjectAnti PDL-1pt_PT
dc.titleImmunotherapy in patients with advanced non-small cell lung cancer lacking driver mutations and future perspectivespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue1pt_PT
oaire.citation.startPage122pt_PT
oaire.citation.titleCancerspt_PT
oaire.citation.volume14pt_PT
person.familyNameCastelo-Branco
person.givenNamePedro
person.identifier.ciencia-idE015-7F8F-5CA1
person.identifier.orcid0000-0002-3453-3978
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationbb25b5ad-1769-42be-a7d3-8fe76215aa23
relation.isAuthorOfPublication.latestForDiscoverybb25b5ad-1769-42be-a7d3-8fe76215aa23

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
cancers-14-00122.pdf
Size:
311.48 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

FCB2-Artigos (em revistas ou actas indexadas)